Investors spooked by Kite CAR-T death, but biotech remains certain, FierceBiotech
Investors spooked by Kite CAR-T death, but biotech remains certain Kite Pharma was off by 15% in morning trading after it announced the death of a patient in late April of cerebral edema—the very same fatal outcome that beset rival Juno’s Rocket trial, killing five people and its CAR-T program for JCAR015.